The University of California San Francisco (UCSF) Health Awards has selected CardioWise, Inc. as a Quarterfinalist in the Hospital Diagnostics Category. The awards showcase the health tech industry, showcasing the best new products and technologies in digital health and life sciences. These are the technologies that will define the future of healthcare and are supported by the nation's top health care accelerators, venture capitalists, and academic leaders.
There were over 1,200 company submissions across 17 categories, vetted by 500+ judges. The winners will be announced at the live event on October 7th at the UCSF Mission Bay Center.
“We are proud to have been chosen as a Quarterfinalist in the Hospital Diagnostic category of the 2021 UCSF Health Awards,” said Jack Coats, CEO of CardioWise. “UCSF is recognized as an expert in digital health and has a superlative reputation, currently in the top 10 in the US News national hospital rankings. For a startup company like CardioWise to have been chosen from over 1200 applicants by a team of prestigious judges, all organized by UCSF, is truly an honor and a tribute to our fine development team led by Geoffrey Dalbow, CardioWise CTO.”
CardioWise is commercializing patented, non-invasive Cardiac CT analysis software that produces a quantified 4D image model of the human heart, called Stretch Quantifier for Endocardial Engraved Zones™ (SQuEEZ™). The FDA 510(k) cleared, heart analysis software, combined with cardiac CT, is a single diagnostic test that can provide quantitative analysis of the myocardium, arteries and valves with an unprecedented level of detail. It has the opportunity to become the new gold standard of care for heart health analysis. CardioWise is a VIC Technology Venture Development portfolio company.
The quarterfinalist in each category can be viewed here: ucsfhealthhub.com/awards/health-awards-quarterfinalists